Shionogi & Co., Ltd. Securities Report - 161st Period (2025/04/01 - 2026/03/31)

Shionogi & Co., Ltd. Securities Report - 161st Period (2025/04/01 - 2026/03/31)

Shionogi & Co., Ltd. has published its 161st Securities Report for the period from April 1, 2025, to March 31, 2026. This report provides a detailed account of the company's performance and financial situation during this period.

The company has been contributing to the improvement of patients' quality of life and the advancement of medicine through the research, development, manufacturing, and sales of pharmaceuticals. This period saw a 10% increase in sales compared to the previous period, and operating profit also increased by 5%. This growth is supported by the company's unique research and development capabilities and the diversity of its product portfolio, leveraging its global network.

Looking ahead, the company will further promote the development of innovative pharmaceuticals and strengthen its patient-centered approach. Additionally, the company will focus on improving its financial situation and aim for sustainable growth.

This report serves as an important indicator for understanding trends in the pharmaceutical industry and is valuable information for investors and industry stakeholders.